Levofloxacin versus ceftriaxone and intravenous amoxicillin/clavulanate in the treatment of community-acquired pneumonia that require hospitalization;Levofloxacino oral frente a ceftriaxona y a amoxicilina/ácido clavulánico intravenosos en el tratamiento de la neumonía adquirida en la comunidad que requiere hospitalización

Medicina Clinica

Volumn 115, Issue 15, 2000, Pages 561-563

  Kalbermatter, Verónica ^a   Bagilet, Daniel ^a,b   Diab, Mario ^a   Javkin, Eduardo ^a  

^a Centro Sanatorio Delta   (Argentina)

^b NONE   (Argentina)

Author keywords

Community acquired pneumonia; Levofloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; LEVOFLOXACIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0342935988     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71625-3     Document Type: Article

References (9)

1. Davis R, Bryscn HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 667-700.
2. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J et al. Pharmacokinetic profile of levofloxacin following once-daily 500 mg, oral or intravenous. Antimicrob Agents Chemother 1997; 41: 2256-2260.
3. Fish DM, Chow AT. The clnical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-119.
4. Ortho Pharmaceutical Corporation and Mac Neil Pharmaceutical Once a day Levaquin tablets injection. Product information, Raritan, NJ, EE.UU. 09969-0602.
5. Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998, 56: 487-515.
6. Campell D. Commentary on the 1993 American Thoracic Society Guidelines for the treatment of community-acquired pneumonia. Chest 1999; 115: S14-S18.
7. Farr BM, Sloman A and Fish MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115: 428-436.
8. Fine MJ, Auble TE, Yearly DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
9. Berstein JM. Treatment of community acquired pneumonia IDSA guidelines. Chest 1999; 115: S9-S13.